Valturna (Novartis), a tablet combining aliskiren and valsartan drug , is the first medication to target two key points within the renin angiotensin-aldosterone system. This drug is indicated for the treatment of hypertension that has not been adequately controlled with aliskiren or monotherapy with an angiotensin-receptor blocker and as an initial therapy for patients who may need multiple drugs to achieve their blood pressure (BP) goals.
Valsartan drug is the active ingredient in Diovan drug, and aliskiren is the active ingredient in Tekturna, a direct renin inhibitor. Valturna appears to offer greater reductions in BP than either drug alone.
The approval was based primarily on a pivotal eight-week randomized, double-blind clinical trial involving approximately 1,800 patients.
The tablets contain aliskiren and valsartan in two strengths: 150 mg/160 mg and 300 mg/320 mg.
Sources: www.pharma.us.novartis. com; Medical News Today, September 17, 2009